



FOR IMMEDIATE RELEASE

The New Zealand Venture Investment Fund (NZVIF) joins Movac Ltd. in new funding round for Migco Pharmaceuticals Ltd.

[Rangiora, New Zealand] – [26 October 2009]--Migco Pharmaceuticals announced today that has raised NZ\$560,000 to continue developing its migraine prevention drug, codenamed MGX-008.

The NZ\$560,000 was secured from the New Zealand Venture Investment Fund (NZVIF) and current investor Movac Ltd. Pacific Channel assisted in the capital raise and facilitated the transaction.

Migco CEO Larry Stenswick said "the fresh funding enables Migco to continue forward with its programme to develop MGX-008 and to prepare for a NZ\$10 million fund raising to support clinical trials". A pilot 'proof of concept' clinical trial involving patients who had failed other treatments has been completed by a respected California neurologist. The results have been published in the journal *Headache*. More than 67% of the patients in the trial positively responded to MGX-008, a drug with a botanical source, and overall the rate of migraine incidence was reduced by more than 50%."

Mr Stenswick said "the new investor funds will be used to complete an investigational new drug application (IND) to the United State Food and Drug Administration (FDA) prior to commencing formal clinical trials."

"It is estimated that about 30 million people suffer migraine in the US alone, and a drug like MGX-008 once confirmed safe and effective in clinical trials will have significant market potential," he said.

Contact: Larry Stenswick
CEO, Migco Pharmaceuticals, Ltd
Ph:+64 3 313 8284 or (mob) +64 21 755 900
stenswick@migco.co.nz

About Migco

Migco Pharmaceuticals is developing and commercializing new drug therapies for the prevention and treatment of migraine headaches. Migco's lead compound, MGX-008 is derived from the bark of *Pinus radiata* and represents a new approach to migraine prevention. It has shown promising indications for the prevention of migraine, and opportunities are emerging for the treatment of other neurological conditions including

ADHD and Alzheimers. Migco has clinical safety data for its lead compound MGX 008, successful human concept trial and a highly skilled and experienced scientific management and governance team to manage the process through to market.

About NZVIF

NZVIF is a New Zealand-based private equity fund of funds investor that manages fund of funds investments as well as direct co-investments.

NZVIF was established by the New Zealand government in 2002, to help build a vibrant venture capital market in New Zealand. We are based in Auckland and governed by a private sector board of directors who provide oversight to our investment management team.

NZVIF currently has \$200 million of funds under management. It is invested through two vehicles:

- the \$160 million Venture Capital Fund of Funds
- the \$40 million Seed Co-investment Fund

About MOVAC

Movac is an investment manager that backs exceptional people with world-beating ideas - ideas that have the potential for rapid and large-scale growth. The philosophy of the Movac Investor Group is to back high growth potential businesses that will provide the foundations for the next wave of prosperity for the New Zealand economy. Movac has a track record of investment success, most notably in **Trademe**.